EGFR L747_P753delinsS

CI-VAR-00002402Explore in graph →ClinVar 16608 CIViC 1012 rs121913438

Curated evidence

Evidence by cancer (10 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–10 of 10 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR L747_P753delinsS	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4270 In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L747_P753insS mutation was associated with resistance to erlotinib treatment. The patient surv… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma8
EGFR L747_P753delinsS	Afatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2610 In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16608	Likely pathogenic; drug response	no assertion criteria provided	0	Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic; Tyrosine kinase inhibitor response; Lung adenocarcinoma; Neoplasm	somatic	4	Oct 28, 2006	clinvar

Pancreatic Adenocarcinoma1
EGFR L747_P753delinsS	Erlotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID6005 Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the panc… (full text at CIViC) PMID 28874593 · Cecchini et al., 2017 · Open in CIViC	civic